Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex
Denali Capital Acquisition Corp. Business Combination: The SEC has declared effective Denali's registration statement for a proposed business combination with Semnur Pharmaceuticals, scheduled for a shareholder vote on September 3, 2025.
Post-Closing Company Name Change: Upon completion of the business combination, the new entity will be renamed "Semnur Pharmaceuticals, Inc." and aims to list its common stock on Nasdaq, pending approval.
Trade with 70% Backtested Accuracy
Analyst Views on SCLXW
No data
About the author
SCILEX HOLDING CO PLANS TO LAUNCH DREAM BOWL TOKENS ON BICONOMY EXCHANGE
- Company Announcement: Cilex Holding Co. intends to list Dream Bowl tokens on the Biconomy exchange.
- Market Impact: This move is expected to enhance the visibility and trading opportunities for Dream Bowl tokens in the cryptocurrency market.
SCILEX HOLDING COMPANY DECLARES DIVIDEND OF DREAM BOWL I MEME COIN TOKENS FOR COMMON STOCKHOLDERS AND OTHER QUALIFIED EQUITY SECURITY HOLDERS, RECORD DATE SET FOR APRIL 30, 2026
- Dividend Announcement: Cilex Holding Company has announced a dividend of Dream Bowl Lime Meme Coin to holders of common stock and other eligible equity securities.
- Record Date: The record date for this dividend distribution is set for April 30, 2026.
SCILEX HOLDING COMPANY INVESTS $20 MILLION IN QUANTUM SCAN HOLDINGS, INC. TO TAP INTO TRILLION-DOLLAR PREVENTIVE DIAGNOSIS AND PROGNOSIS SECTORS
Investment Announcement: Cilex Holding Company has announced a strategic investment of $20 million in Quantum Scan Holdings, Inc.
Market Focus: The investment aims to target the trillion-dollar preventive diagnostics and prognostics markets.
Scilex Holding Company Secures Global Exclusive License for Tokenizing and Monetizing Real-World Assets in Genomics, DNA Data, Diagnostics, Therapeutics, and Genetic Drug Information from Datavault AI
Scilex In-Licenses AI Technology: Scilex Holding Company has secured a worldwide exclusive license for Datavault AI's proprietary technology, aimed at creating a Biotech Exchange platform for secure tokenization and trading of biotech assets, including genomic and drug information.
Potential Market Impact: The company estimates a significant opportunity to tokenize approximately $2 trillion in pharmaceutical and diagnostic sales, which could provide alternative funding avenues for developing therapeutic products.
Intellectual Property Portfolio: The licensing agreement includes a robust portfolio of patents related to tokenization methods and secure data handling, which will support the infrastructure for the Biotech Exchange.
Financial Terms of the License: Scilex will pay a total of $10 million in non-refundable license fees in installments, with additional milestone payments to Datavault potentially reaching $2.55 billion based on sales achievements.
Scilex Holding Company Unveils $150 Million Strategic Investment in Bitcoin for Datavault AI
Scilex Investment in Datavault: Scilex Holding Company has announced a $150 million investment in Datavault AI Inc. to support its growth in supercomputing infrastructure and data monetization, aiming to capitalize on the expanding biotech data market.
Market Potential and Strategy: The investment aligns with the projected growth of the global AI market and the biotech data monetization sector, which is expected to reach $30-50 billion by 2024, leveraging blockchain technology and AI-driven analytics for secure data trading.
Share Acquisition Details: Under the agreement, Scilex will acquire up to 278 million shares of Datavault common stock, with specific terms for share issuance contingent on stockholder approval, while maintaining the right to nominate directors based on ownership stakes.
Leadership Insights: Scilex's CEO emphasized the strategic fit of Datavault's technologies with the biotech sector's needs, highlighting the potential for significant revenue generation and market transformation through their collaboration.
Scilex Holding Company Forms Partnership with Biconomy.com to Develop Future Cryptocurrency Strategies and Manage Treasury Operations
Collaboration Announcement: Scilex Holding Company has signed a non-binding Memorandum of Understanding with Biconomy.com to explore cryptocurrency and treasury management strategies, including global trading services for digital assets and a treasury management strategy focused on security and compliance.
Product Development Focus: Scilex is dedicated to developing non-opioid pain management products, with existing FDA-approved products like ZTlido®, ELYXYB®, and Gloperba®, as well as several product candidates in various stages of clinical development targeting acute and chronic pain.
SCILEX HOLDING CO PLANS TO LAUNCH DREAM BOWL TOKENS ON BICONOMY EXCHANGE
- Company Announcement: Cilex Holding Co. intends to list Dream Bowl tokens on the Biconomy exchange.
- Market Impact: This move is expected to enhance the visibility and trading opportunities for Dream Bowl tokens in the cryptocurrency market.
SCILEX HOLDING COMPANY DECLARES DIVIDEND OF DREAM BOWL I MEME COIN TOKENS FOR COMMON STOCKHOLDERS AND OTHER QUALIFIED EQUITY SECURITY HOLDERS, RECORD DATE SET FOR APRIL 30, 2026
- Dividend Announcement: Cilex Holding Company has announced a dividend of Dream Bowl Lime Meme Coin to holders of common stock and other eligible equity securities.
- Record Date: The record date for this dividend distribution is set for April 30, 2026.
SCILEX HOLDING COMPANY INVESTS $20 MILLION IN QUANTUM SCAN HOLDINGS, INC. TO TAP INTO TRILLION-DOLLAR PREVENTIVE DIAGNOSIS AND PROGNOSIS SECTORS
Investment Announcement: Cilex Holding Company has announced a strategic investment of $20 million in Quantum Scan Holdings, Inc.
Market Focus: The investment aims to target the trillion-dollar preventive diagnostics and prognostics markets.
Scilex Holding Company Secures Global Exclusive License for Tokenizing and Monetizing Real-World Assets in Genomics, DNA Data, Diagnostics, Therapeutics, and Genetic Drug Information from Datavault AI
Scilex In-Licenses AI Technology: Scilex Holding Company has secured a worldwide exclusive license for Datavault AI's proprietary technology, aimed at creating a Biotech Exchange platform for secure tokenization and trading of biotech assets, including genomic and drug information.
Potential Market Impact: The company estimates a significant opportunity to tokenize approximately $2 trillion in pharmaceutical and diagnostic sales, which could provide alternative funding avenues for developing therapeutic products.
Intellectual Property Portfolio: The licensing agreement includes a robust portfolio of patents related to tokenization methods and secure data handling, which will support the infrastructure for the Biotech Exchange.
Financial Terms of the License: Scilex will pay a total of $10 million in non-refundable license fees in installments, with additional milestone payments to Datavault potentially reaching $2.55 billion based on sales achievements.
Scilex Holding Company Unveils $150 Million Strategic Investment in Bitcoin for Datavault AI
Scilex Investment in Datavault: Scilex Holding Company has announced a $150 million investment in Datavault AI Inc. to support its growth in supercomputing infrastructure and data monetization, aiming to capitalize on the expanding biotech data market.
Market Potential and Strategy: The investment aligns with the projected growth of the global AI market and the biotech data monetization sector, which is expected to reach $30-50 billion by 2024, leveraging blockchain technology and AI-driven analytics for secure data trading.
Share Acquisition Details: Under the agreement, Scilex will acquire up to 278 million shares of Datavault common stock, with specific terms for share issuance contingent on stockholder approval, while maintaining the right to nominate directors based on ownership stakes.
Leadership Insights: Scilex's CEO emphasized the strategic fit of Datavault's technologies with the biotech sector's needs, highlighting the potential for significant revenue generation and market transformation through their collaboration.
Scilex Holding Company Forms Partnership with Biconomy.com to Develop Future Cryptocurrency Strategies and Manage Treasury Operations
Collaboration Announcement: Scilex Holding Company has signed a non-binding Memorandum of Understanding with Biconomy.com to explore cryptocurrency and treasury management strategies, including global trading services for digital assets and a treasury management strategy focused on security and compliance.
Product Development Focus: Scilex is dedicated to developing non-opioid pain management products, with existing FDA-approved products like ZTlido®, ELYXYB®, and Gloperba®, as well as several product candidates in various stages of clinical development targeting acute and chronic pain.
